Metastatic Breast Cancer
Conference Coverage
After 48 years, NCI aims to track breast cancer recurrences
News from the FDA/CDC
Margetuximab approved for HER2-positive metastatic breast cancer
The monoclonal antibody margetuximab-cmkb demonstrated superiority over trastuzumab.
Conference Coverage
An all-oral option for advanced HR+, HER2– breast cancer?
Adding the oral taxane tesetaxel to capecitabine improved progression-free survival.
Conference Coverage
Pembro benefits in mTNBC regardless of chemo type
Conference Coverage
First-in-class ADC has benefit across mTNBC subgroups
For women with pretreated metastatic triple-negative breast cancer, sacituzumab govitecan improved outcomes regardless of target protein...
Conference Coverage
CTCs predict overall survival in metastatic breast cancer
New data seem to support using circulating tumor cells to assess treatment efficacy in practice, but an expert has doubts.
From the Journals
Should CTCs guide treatment choice in HR+, HER2– breast cancer?
Survival outcomes were similar whether treatment choice was guided by circulating tumor cell counts or clinical factors.
News
Pembrolizumab approved for triple-negative breast cancer
This is the first breast cancer indication for pembrolizumab.
Considerations In The Management Of HER2+ Breast Cancer
Conference Coverage
Divergent findings with paclitaxel and nab-paclitaxel in TNBC
Atezolizumab may improve survival when it’s added to nab-paclitaxel but not paclitaxel, studies suggest.
Conference Coverage
First-in-class ADC ups survival in mTNBC
Sacituzumab govitecan prolonged progression-free and overall survival.